{"id":"durvalumab-soc-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Immune-mediated pneumonitis"},{"rate":null,"effect":"Immune-mediated hepatitis"},{"rate":null,"effect":"Immune-mediated colitis"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":{"chemblId":"CHEMBL3301587","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Durvalumab is a PD-L1 inhibitor that prevents the interaction between PD-L1 on tumor cells and PD-1/PD-L2 on immune cells, thereby releasing the brake on T-cell-mediated immunity. When combined with standard-of-care chemotherapy, the chemotherapy provides direct cytotoxic effects and immunogenic cell death, while durvalumab amplifies the resulting anti-tumor immune response. This combination approach targets both tumor cells directly and the immunosuppressive tumor microenvironment.","oneSentence":"Durvalumab blocks PD-L1 on tumor cells to restore immune recognition and killing, combined with standard chemotherapy to enhance anti-tumor activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:06.535Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Unresectable stage III non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy"},{"name":"First-line treatment of advanced or metastatic NSCLC in combination with chemotherapy"}]},"trialDetails":[{"nctId":"NCT06058377","phase":"PHASE3","title":"Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-11-27","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma","enrollment":3680},{"nctId":"NCT06694454","phase":"PHASE1, PHASE2","title":"Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma","enrollment":60},{"nctId":"NCT06467357","phase":"PHASE3","title":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-12","conditions":"Biliary Tract Cancer","enrollment":620},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT03164616","phase":"PHASE3","title":"Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-06-01","conditions":"Non Small Cell Lung Cancer NSCLC","enrollment":1186},{"nctId":"NCT03003962","phase":"PHASE3","title":"Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-01-02","conditions":"Non Small Cell Lung Carcinoma NSCLC","enrollment":669},{"nctId":"NCT02453282","phase":"PHASE3","title":"Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2015-07-21","conditions":"Non-Small-Cell Lung Carcinoma NSCLC","enrollment":1118},{"nctId":"NCT02542293","phase":"PHASE3","title":"Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2015-11-03","conditions":"Non Small Cell Lung Carcinoma NSCLC","enrollment":953},{"nctId":"NCT03775486","phase":"PHASE2","title":"Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-12-21","conditions":"Non-small Cell Lung Cancer NSCLC","enrollment":401},{"nctId":"NCT03682068","phase":"PHASE3","title":"Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-09-27","conditions":"Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer","enrollment":1246},{"nctId":"NCT06746116","phase":"PHASE3","title":"A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-12-30","conditions":"Advanced or Recurrent Endometrial Cancer","enrollment":45},{"nctId":"NCT06124118","phase":"PHASE1","title":"Tumor Treating Fields for Locally Advanced NSCLC","status":"RECRUITING","sponsor":"University of Utah","startDate":"2024-04-04","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT03519971","phase":"PHASE3","title":"Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-03-29","conditions":"Non-Small Cell Lung Cancer","enrollment":328},{"nctId":"NCT04644289","phase":"PHASE2","title":"WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC","status":"RECRUITING","sponsor":"AGO Research GmbH","startDate":"2022-05-05","conditions":"Epithelial Ovarian Cancer","enrollment":60},{"nctId":"NCT07172412","phase":"PHASE2","title":"Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-11","conditions":"Extensive Stage Lung Small Cell Cancer","enrollment":165},{"nctId":"NCT06840782","phase":"PHASE3","title":"First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09-09","conditions":"Oligometastatic Non-small Cell Lung Cancer (NSCLC)","enrollment":124},{"nctId":"NCT05712356","phase":"PHASE2","title":"A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lisata Therapeutics, Inc.","startDate":"2023-08-24","conditions":"Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma","enrollment":67},{"nctId":"NCT04449861","phase":"PHASE3","title":"Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-12-07","conditions":"Small Cell Lung Carcinoma Extensive Disease","enrollment":166},{"nctId":"NCT04385368","phase":"PHASE3","title":"Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-07-17","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":89},{"nctId":"NCT03830866","phase":"PHASE3","title":"Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-02-15","conditions":"Locally Advanced Cervical Cancer","enrollment":770},{"nctId":"NCT03472274","phase":"PHASE2","title":"Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)","status":"COMPLETED","sponsor":"Fundacion CRIS de Investigación para Vencer el Cáncer","startDate":"2018-10-25","conditions":"Bladder Cancer","enrollment":101},{"nctId":"NCT05383001","phase":"PHASE2","title":"Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)","status":"WITHDRAWN","sponsor":"AIO-Studien-gGmbH","startDate":"2022-05-20","conditions":"NSCLC Stage IV","enrollment":""},{"nctId":"NCT02551159","phase":"PHASE3","title":"Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-10-15","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":823},{"nctId":"NCT04982549","phase":"PHASE2","title":"A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2021-01-21","conditions":"Unresectable Stage III NSCLC","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MEDI4736"],"phase":"phase_3","status":"active","brandName":"Durvalumab + SoC chemotherapy","genericName":"Durvalumab + SoC chemotherapy","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Durvalumab blocks PD-L1 on tumor cells to restore immune recognition and killing, combined with standard chemotherapy to enhance anti-tumor activity. Used for Unresectable stage III non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy, First-line treatment of advanced or metastatic NSCLC in combination with chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}